{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T13:54:33Z","timestamp":1726494873624},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"CARIPLO Foundation (Vaccine Initiative) and by the Ministry of Health, Italy","award":["RF-2010-2318269"],"award-info":[{"award-number":["RF-2010-2318269"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jviromet.2017.10.003","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T20:32:01Z","timestamp":1507667521000},"page":"7-14","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Strategies to obtain multiple recombinant modified vaccinia Ankara vectors. Applications to influenza vaccines"],"prefix":"10.1016","volume":"251","author":[{"given":"Andrea","family":"Barbieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Panigada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Soprana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Di Mario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Gubinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Recagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Donatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria R.","family":"Castrucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio G.","family":"Siccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2017.10.003_bib0005","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/mt.2013.162","article-title":"Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virusres.2013.12.002","article-title":"Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation","volume":"180","author":"Calvo-Pinilla","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/irv.12221","article-title":"Modified vaccinia virus Ankara expressing the hemagglutinin of pandemic (H1N1) 2009 virus induces cross-protective immunity against Eurasian \u2018avian-like' H1N1 swine viruses in mice","volume":"8","author":"Castrucci","year":"2014","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0030","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1128\/JVI.79.5.2678-2688.2005","article-title":"Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region","volume":"79","author":"Chen","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0035","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1089\/104303402753812520","article-title":"Clinical protocol: a phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus","volume":"13","author":"Corona Gutierrez","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.gastro.2014.03.007","article-title":"Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a phase 2 study of patients with chronic HCV infection","volume":"147","author":"Di Bisceglie","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jviromet.2008.10.026","article-title":"Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection","volume":"156","author":"Di Lullo","year":"2009","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jviromet.2009.09.016","article-title":"The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use","volume":"163","author":"Di Lullo","year":"2010","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0055","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/20477724.2016.1275465","article-title":"Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins","volume":"111","author":"Di Mario","year":"2017","journal-title":"Path Glob. Health"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0060","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/JVI.62.6.1849-1854.1988","article-title":"Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors","volume":"62","author":"Falkner","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0065","doi-asserted-by":"crossref","first-page":"e16247","DOI":"10.1371\/journal.pone.0016247","article-title":"Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity","volume":"6","author":"Hessel","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0070","doi-asserted-by":"crossref","first-page":"e88340","DOI":"10.1371\/journal.pone.0088340","article-title":"MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses","volume":"9","author":"Hessel","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0075","first-page":"7942","article-title":"Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses","volume":"63","author":"Hodge","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.virol.2005.04.009","article-title":"Dominant negative selection of vaccinia virus using a thymidine kinase\/thymidylate kinase fusion gene and the prodrug azidothymidine","volume":"337","author":"Holzer","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0085","doi-asserted-by":"crossref","first-page":"8394","DOI":"10.1128\/JVI.77.15.8394-8407.2003","article-title":"Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L","volume":"77","author":"Hornemann","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0090","doi-asserted-by":"crossref","first-page":"13300","DOI":"10.1128\/JVI.01532-14","article-title":"Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene","volume":"88","author":"Kamlangdee","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0095","doi-asserted-by":"crossref","first-page":"e18556","DOI":"10.1371\/journal.pone.0018556","article-title":"High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice","volume":"6","author":"Kim","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0100","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1038\/mt.2014.109","article-title":"Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations","volume":"22","author":"Kimani","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0105","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1128\/CVI.00006-10","article-title":"Highly persistent and effective prime\/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant","volume":"17","author":"Kolibab","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cid\/cis327","article-title":"Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans","volume":"55","author":"Lillie","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0115","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1128\/JVI.49.3.857-864.1984","article-title":"General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes","volume":"49","author":"Mackett","year":"1984","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0120","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/eji.201242922","article-title":"Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine","volume":"43","author":"Mullarkey","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0125","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.4049\/jimmunol.156.7.2473","article-title":"Importance of MHC class a2 and a3 domains in the recognition of self and non-self MHC molecules","volume":"156","author":"Newberg","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0130","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.4049\/jimmunol.0803467","article-title":"Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice","volume":"182","author":"Poon","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0135","doi-asserted-by":"crossref","first-page":"e62778","DOI":"10.1371\/journal.pone.0062778","article-title":"Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine","volume":"8","author":"Powell","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jviromet.2011.03.013","article-title":"Joint production of prime\/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene","volume":"174","author":"Soprana","year":"2011","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0145","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2144\/00286st04","article-title":"Transient host range selection for genetic engineering of modified vaccinia virus Ankara","volume":"28","author":"Staib","year":"2000","journal-title":"Biotechniques"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0150","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2144\/03344bm02","article-title":"Improved host range selection for recombinant modified vaccinia virus Ankara","volume":"34","author":"Staib","year":"2003","journal-title":"Biotechniques"},{"key":"10.1016\/j.jviromet.2017.10.003_bib0155","first-page":"77","article-title":"Construction and isolation of recombinant MVA","volume":"269","author":"Staib","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0160","first-page":"263","article-title":"Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Current drug targets","volume":"3","author":"Sutter","year":"2003","journal-title":"Infect. Disord."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0165","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0264-410X(94)90341-7","article-title":"A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus","volume":"12","author":"Sutter","year":"1994","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jviromet.2017.10.003_bib0170","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1101\/pdb.prot067892","article-title":"Verification of 2A peptide cleavage","volume":"2012","author":"Szymczak-Workman","year":"2012","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0175","doi-asserted-by":"crossref","first-page":"e1004524","DOI":"10.1371\/journal.ppat.1004524","article-title":"Human cytomegalovirus vaccine based on the envelope gH\/gL pentamer complex","volume":"10","author":"Wussow","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jviromet.2017.10.003_bib0180","doi-asserted-by":"crossref","first-page":"e3101","DOI":"10.1371\/journal.pntd.0003101","article-title":"Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge","volume":"8","author":"van den Doel","year":"2014","journal-title":"PLoS Negl. Trop. Dis."}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093417301349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093417301349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T23:09:29Z","timestamp":1693091369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093417301349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":36,"alternative-id":["S0166093417301349"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2017.10.003","relation":{},"ISSN":["0166-0934"],"issn-type":[{"type":"print","value":"0166-0934"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies to obtain multiple recombinant modified vaccinia Ankara vectors. Applications to influenza vaccines","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2017.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}